AARD

Aardvark Therapeutics, Inc. (AARD) has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimates over the past three months, with consensus estimates increasing 12.4%. The upgrade reflects improved business fundamentals and positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation.

Rosen Law Firm is notifying investors in Aardvark Therapeutics, Inc. of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.

Rosen Law Firm reminds investors in Aardvark Therapeutics who purchased securities during the IPO on February 13, 2025 through May 14, 2026 of an October 13, 2026 deadline to nominate a lead plaintiff. The lawsuit alleges that defendants made material false and misleading statements regarding the safety and commercial prospects of ARD-101, causing investor losses when the truth was revealed.

Hagens Berman announces a securities class action lawsuit against Aardvark Therapeutics for allegedly making materially false statements about ARD-101's safety. The company failed to disclose cardiac observations during trials, leading to a voluntary pause of the Phase 3 HERO trial in February 2026 (56% stock decline) and an FDA clinical hold in May 2026 (32.1% additional decline). Investors with substantial losses have until October 13, 2026, to become lead plaintiffs.

Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, Inc. for allegedly making materially false and misleading statements regarding the safety and prospects of its drug ARD-101. Investors who purchased securities during the IPO on February 13, 2025 or between February 13, 2025 and May 14, 2026 may be eligible to join the class action. The deadline to serve as lead plaintiff is October 13, 2026.

Grabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes.

Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, with an October 13, 2026 deadline for investors to serve as lead plaintiff. The lawsuit alleges that defendants made materially false and misleading statements regarding the safety and prospects of their drug candidate ARD-101, causing investor damages when the true details emerged.

Rosen Law Firm has announced multiple securities class action lawsuits against Aardvark Therapeutics, FuelCell Energy, and XTI Aerospace. The primary case involves Aardvark Therapeutics, where investors claim the company made materially false statements about the safety and prospects of its ARD-101 drug candidate in its IPO registration statement and throughout the class period. Investors have until October 13, 2026 to become lead plaintiffs in the Aardvark case.

Rosen Law Firm is reminding investors in Aardvark Therapeutics, Inc. (AARD) of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, causing investor damages when the truth entered the market. The firm is also investigating claims related to Hyliion Holdings Corp. (HYLN) and FLOW cryptocurrency.

Aardvark Therapeutics reported exploratory efficacy data from its early-terminated Phase 3 HERO trial for ARD-101, a hunger-suppressing therapy for Prader-Willi syndrome. The drug showed modest reductions in hyperphagia scores and was generally well-tolerated, though one cardiac serious adverse event occurred at the highest dose in combination with another drug. The FDA lifted the clinical hold, allowing the company to resume development at lower doses and plan a new Phase 3 trial.

A class action lawsuit has been filed against Aardvark Therapeutics in the U.S. District Court for the Southern District of California. The lawsuit alleges that defendants made materially false and misleading statements in the company's IPO registration statement and throughout the class period (February 13, 2025 to May 14, 2026), specifically regarding the safety and commercial prospects of their drug ARD-101. Investors who purchased shares during this period can apply to be lead plaintiff by October 13, 2026.

Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold.

A class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging securities fraud. The complaint claims that offering documents contained untrue statements and that the company made materially false and misleading statements regarding the safety and prospects of its drug ARD-101. Investors who purchased shares during the IPO on February 13, 2025, or between that date and May 14, 2026, may be eligible to join the case.

A class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging securities fraud related to its February 2025 IPO and subsequent period through May 2026. The complaint claims the company made materially false and misleading statements about the safety and prospects of its drug candidate ARD-101, and that offering documents were negligently prepared. Investors who purchased shares during the class period are encouraged to join the lawsuit.

A class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging that offering documents contained false statements and that the company made materially misleading statements about the safety and prospects of its drug ARD-101. The lawsuit covers investors who purchased securities during the IPO on February 13, 2025, and through May 14, 2026. The lead plaintiff deadline is October 13, 2026.